KEGG pathways enriched for interacted genes |
pathway name | pathway description | target genes enrich in pathway | p-value |
|
hsa05210
|
Colorectal cancer |
IGF1R,BCL2,RAF1,MAP2K1,MAPK3,CASP3, |
1.30E-7 |
hsa05215
|
Prostate cancer |
IGF1R,BCL2,RAF1,MAP2K1,MAPK3, |
1.03E-5 |
hsa05200
|
Pathways in cancer |
IGF1R,BCL2,RAF1,MAP2K1,MAPK3,CASP3, |
1.10E-4 |
hsa05214
|
Glioma |
IGF1R,RAF1,MAP2K1,MAPK3, |
1.44E-4 |
hsa04730
|
Long-term depression |
IGF1R,RAF1,MAP2K1,MAPK3, |
1.89E-4 |
|
hsa05218
|
Melanoma |
IGF1R,RAF1,MAP2K1,MAPK3, |
2.06E-4 |
hsa04510
|
Focal adhesion |
IGF1R,BCL2,RAF1,MAP2K1,MAPK3, |
2.55E-4 |
hsa04914
|
Progesterone-mediated oocyte maturation |
IGF1R,RAF1,MAP2K1,MAPK3, |
3.64E-4 |
hsa04722
|
Neurotrophin signaling pathway |
BCL2,RAF1,MAP2K1,MAPK3, |
1.06E-2 |
hsa04650
|
Natural killer cell mediated cytotoxicity |
RAF1,MAP2K1,MAPK3,CASP3, |
1.30E-2 |
hsa05219
|
Bladder cancer |
RAF1,MAP2K1,MAPK3, |
2.31E-2 |
hsa05213
|
Endometrial cancer |
RAF1,MAP2K1,MAPK3, |
3.52E-2 |
hsa05223
|
Non-small cell lung cancer |
RAF1,MAP2K1,MAPK3, |
3.79E-2 |
hsa05221
|
Acute myeloid leukemia |
RAF1,MAP2K1,MAPK3, |
4.37E-2 |
hsa04720
|
Long-term potentiation |
RAF1,MAP2K1,MAPK3, |
5.97E-2 |
hsa05211
|
Renal cell carcinoma |
RAF1,MAP2K1,MAPK3, |
6.31E-2 |
hsa05212
|
Pancreatic cancer |
RAF1,MAP2K1,MAPK3, |
6.67E-2 |
hsa04370
|
VEGF signaling pathway |
RAF1,MAP2K1,MAPK3, |
7.22E-2 |
hsa04662
|
B cell receptor signaling pathway |
RAF1,MAP2K1,MAPK3, |
7.22E-2 |
hsa05220
|
Chronic myeloid leukemia |
RAF1,MAP2K1,MAPK3, |
7.22E-2 |
hsa04664
|
Fc epsilon RI signaling pathway |
RAF1,MAP2K1,MAPK3, |
7.79E-2 |
hsa04010
|
MAPK signaling pathway |
RAF1,MAP2K1,MAPK3,CASP3, |
9.49E-2 |
hsa04012
|
ErbB signaling pathway |
RAF1,MAP2K1,MAPK3, |
9.63E-2 |
hsa04540
|
Gap junction |
RAF1,MAP2K1,MAPK3, |
1.00E-1 |
hsa04666
|
Fc gamma R-mediated phagocytosis |
RAF1,MAP2K1,MAPK3, |
1.14E-1 |
hsa04912
|
GnRH signaling pathway |
RAF1,MAP2K1,MAPK3, |
1.21E-1 |
hsa04916
|
Melanogenesis |
RAF1,MAP2K1,MAPK3, |
1.23E-1 |
hsa04660
|
T cell receptor signaling pathway |
RAF1,MAP2K1,MAPK3, |
1.45E-1 |
hsa04114
|
Oocyte meiosis |
IGF1R,MAP2K1,MAPK3, |
1.51E-1 |
hsa04270
|
Vascular smooth muscle contraction |
RAF1,MAP2K1,MAPK3, |
1.56E-1 |
hsa04910
|
Insulin signaling pathway |
RAF1,MAP2K1,MAPK3, |
2.22E-1 |
hsa04062
|
Chemokine signaling pathway |
RAF1,MAP2K1,MAPK3, |
4.08E-1 |
hsa04320
|
Dorso-ventral axis formation |
MAP2K1,MAPK3, |
4.34E-1 |
hsa05216
|
Thyroid cancer |
MAP2K1,MAPK3, |
5.02E-1 |
hsa04810
|
Regulation of actin cytoskeleton |
RAF1,MAP2K1,MAPK3, |
5.26E-1 |
hsa05020
|
Prion diseases |
MAP2K1,MAPK3, |
6.03E-1 |
hsa05014
|
Amyotrophic lateral sclerosis (ALS) |
BCL2,CASP3, |
9.00E-1 |
|
|
|
|
|
|
Gene ontology terms enriched for interacted genes |
GO terms | GO terms description | target genes enrich in GO term | p-value |
|
GO:0006468
|
protein amino acid phosphorylation |
IGF1R,BCL2,RAF1,MAP2K1,MAPK3,WEE1, |
2.65E-4 |
GO:0016310
|
phosphorylation |
IGF1R,BCL2,RAF1,MAP2K1,MAPK3,WEE1, |
6.16E-4 |
GO:0006793
|
phosphorus metabolic process |
IGF1R,BCL2,RAF1,MAP2K1,MAPK3,WEE1, |
1.50E-2 |
GO:0006796
|
phosphate metabolic process |
IGF1R,BCL2,RAF1,MAP2K1,MAPK3,WEE1, |
1.50E-2 |
GO:0030335
|
positive regulation of cell migration |
IGF1R,BCL2,MAP2K1, |
3.18E-2 |
|
GO:0051272
|
positive regulation of cell motion |
IGF1R,BCL2,MAP2K1, |
3.84E-2 |
GO:0040017
|
positive regulation of locomotion |
IGF1R,BCL2,MAP2K1, |
3.84E-2 |
GO:0048872
|
homeostasis of number of cells |
BCL2,TCEA1,CASP3, |
4.00E-2 |
GO:0007265
|
Ras protein signal transduction |
RAF1,MAP2K1,MAPK3, |
4.40E-2 |
GO:0010604
|
positive regulation of macromolecule metabolic process |
IGF1R,RUNX2,BCL2,TCEA1,MAP2K1, |
7.20E-2 |
GO:0045165
|
cell fate commitment |
RUNX2,BCL2,CASP3, |
7.59E-2 |
|
|
|
|
|
|